Strategic Global Advisors LLC lowered its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 85.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,712 shares of the company’s stock after selling 535,388 shares during the period. Strategic Global Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $810,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of TEVA. Renaissance Technologies LLC boosted its stake in shares of Teva Pharmaceutical Industries by 272.6% during the 2nd quarter. Renaissance Technologies LLC now owns 9,786,063 shares of the company’s stock worth $90,325,000 after acquiring an additional 7,159,900 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Teva Pharmaceutical Industries by 12.5% in the 2nd quarter. Northern Trust Corp now owns 7,610,010 shares of the company’s stock worth $70,239,000 after acquiring an additional 846,650 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 0.5% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,348,213 shares of the company’s stock worth $49,364,000 after acquiring an additional 26,600 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Teva Pharmaceutical Industries by 12.9% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,005,074 shares of the company’s stock worth $36,967,000 after purchasing an additional 458,751 shares during the period. Finally, Swiss National Bank raised its position in shares of Teva Pharmaceutical Industries by 11.6% during the second quarter. Swiss National Bank now owns 3,985,099 shares of the company’s stock worth $36,782,000 after purchasing an additional 413,800 shares during the period. 57.85% of the stock is currently owned by institutional investors.

Shares of TEVA stock traded up $0.17 during trading on Wednesday, hitting $8.31. 27,531,073 shares of the company were exchanged, compared to its average volume of 21,418,584. The business’s 50-day simple moving average is $7.20 and its 200 day simple moving average is $11.30. Teva Pharmaceutical Industries Ltd has a twelve month low of $6.07 and a twelve month high of $25.13. The firm has a market capitalization of $8.83 billion, a price-to-earnings ratio of 2.97, a P/E/G ratio of 0.78 and a beta of 1.68. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The firm had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. During the same quarter in the prior year, the business earned $0.78 EPS. The company’s revenue for the quarter was down 7.7% compared to the same quarter last year. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.25 earnings per share for the current fiscal year.

TEVA has been the subject of a number of recent analyst reports. SunTrust Banks decreased their price target on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating for the company in a research report on Thursday, August 8th. CIBC upgraded Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 price objective on the stock in a report on Monday, June 3rd. Raymond James reduced their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Morgan Stanley cut shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $16.00 to $6.00 in a report on Monday, July 15th. Finally, Barclays began coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, June 11th. They issued an “underweight” rating and a $8.00 target price on the stock. Six research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus price target of $12.80.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: Net Asset Value

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.